1753P Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France

M.S Negrier,F.P Colrat,J Bonastre,C Chamielec,S Teitsson,C Knight,L Ni,J Chevalier,A-F Gaudin,M Roupret,S Branchoux

doi:10.1016/j.annonc.2022.07.1831

1753P Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France

M.S Negrier, F.P Colrat + Show 9 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1831

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Institut Gustave Roussy

#High Risk Of Recurrence #Nivolumab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

NIVO is the first immuno-oncology drug to demonstrate significantly improved disease-free (DF) survival for the adjuvant treatment of patients (pts) with MIUC-HR who had undergone radical resection, compared to placebo (PBO). The objective of this study was to assess the CE of NIVO versus surveillance (SURV), a proxy of PBO, in this indication in France.

Full Text